Basic Theophylline Information

• INN (International Nonproprietary Name): not specified
• Brand Names Available In United Kingdom: not specified
• ATC Code: not specified
• Forms & Dosages: Tablets (immediate‑release and prolonged‑release), strengths vary by manufacturer; common prolonged‑release strengths listed in templates include 200–400 mg; packaging typically blisters or bottles (exact strengths and pack sizes not specified).
• Manufacturers In United Kingdom: Global manufacturers cited in the source include Pfizer, Johnson & Johnson, GSK, Sanofi, Bayer, Novartis and AstraZeneca; specific UK manufacturers for this product are not specified.
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Status depends on indication, formulation strength and national rules; classification may be prescription‑only or OTC depending on product and indication.

Research Highlights — UK & EU Evidence (2022–Mid‑2024)

Clinicians commonly ask whether modern evidence supports theophylline as a useful option in UK and European practice.

Recent UK and EU research through mid‑2024 confirms theophylline remains a niche but pharmacologically important bronchodilator with a narrow therapeutic index.

Randomised and observational studies in COPD cohorts and steroid‑dependent asthma populations reported small but clinically meaningful improvements in FEV1 and exacerbation rates when low‑dose theophylline was used as an add‑on anti‑inflammatory agent.

Effect sizes across trials were modest and heterogeneous, with clearer benefit seen in COPD patients prone to exacerbations compared with stable, mild asthma cohorts.

Pharmacokinetic investigations from UK university hospitals emphasise variable clearance affected by smoking, age and polypharmacy, supporting routine therapeutic drug monitoring.

Safety analyses drawn from MHRA Yellow Card summaries and EU vigilance datasets show serious adverse events such as arrhythmia and seizures are uncommon but clustered where monitoring is absent or interacting drugs are prescribed.

Cost‑effectiveness modelling in several European settings suggests theophylline can be economical where monitoring infrastructure exists, but not when monitoring or admissions for toxicity are frequent.

These findings jointly support targeted use of theophylline where benefits are likely and monitoring is available.

Clinical Effectiveness In The UK — NHS Treatment Outcomes And Real‑World Data

Patients often want to know what the NHS sees in everyday practice regarding theophylline.

Within NHS practice theophylline is generally reserved for patients not controlled on first‑line inhaled therapies or where inhaled steroids or biologics are unsuitable.

Real‑world audits from UK respiratory clinics report modest average improvements in symptom control and exercise tolerance with theophylline.

Benefits appear more consistent in COPD with frequent exacerbations than in stable, mild asthma cohorts.

NHS datasets indicate hospital admissions related to theophylline toxicity are rare but disproportionately affect elderly patients with comorbidities and polypharmacy.

Therapeutic drug monitoring integrated into secondary‑care respiratory pathways reduces adverse events and optimises dosing.

Patient‑reported outcomes emphasise mixed tolerability; some patients value oral dosing convenience while others prefer inhaled agents to avoid systemic side effects.

In practice, respiratory consultants and specialist nurses document monitoring plans and stop criteria before initiating theophylline on NHS pathways.

Indications And Expanded Uses — MHRA‑Labelled And Off‑Label Practice

Patients ask where theophylline fits in modern treatment pathways and what counts as "off‑label".

MHRA‑aligned indications in the UK principally cover adjunctive bronchodilator therapy in COPD and severe, steroid‑dependent asthma where inhaled options are insufficient.

Common off‑label uses in UK clinics include low‑dose theophylline for steroid‑sparing anti‑inflammatory effect and adjunct therapy in nocturnal asthma.

Specialist prescribing usually requires documented therapeutic drug monitoring plans and clear stop criteria in the notes.

Use in paediatric practice is limited and tightly controlled; many paediatric pulmonologists favour inhaled treatments first.

• MHRA‑Approved Uses: Adjunctive bronchodilator in COPD; adjunct in severe steroid‑dependent asthma (as per local specialist guidance).
• Common Off‑Label Uses: Low‑dose steroid‑sparing therapy; adjunct for nocturnal asthma symptoms under specialist supervision.

Definitions commonly used in practice are:

• Low‑Dose Theophylline: Doses producing plasma concentrations at the lower therapeutic range, used for anti‑inflammatory effect rather than bronchodilation.
• Therapeutic‑Range Theophylline: Doses aimed at traditional bronchodilator targets, typically measured with TDM to 10–20 μg/mL (10–20 mg/L).

Regulatory note: clinicians are expected to balance the narrow therapeutic window against potential benefit and to report suspected adverse reactions via the Yellow Card scheme.

Composition And Brand Landscape — Ingredients, UK Brands, Generics And Packaging

People often ask which preparations are available and whether brands differ in practical ways.

The active ingredient is theophylline (INN).

The UK market contains immediate‑release and prolonged‑release oral formulations supplied by named brands historically and by multiple generics.

Recognised brand names historically include Uniphyllin Continus for prolonged‑release formulations, alongside many generics.

Typical prolonged‑release tablet strengths reported in practice include 200 mg and 400 mg, but exact strengths vary by manufacturer; always check the SmPC or label.

Excipients differ by manufacturer and may include lactose or other substances; check the SmPC for allergen information.

Generics are widely available and community pharmacies, hospital pharmacies and major chains commonly stock theophylline preparations on prescription.

Note: always confirm brand‑specific packaging and labelling from the SmPC or the MHRA where required for product pages and patient information.

Contraindications And Special Precautions — High‑Risk Groups And Lifestyle Restrictions

Patients frequently ask who should avoid theophylline altogether.

Absolute contraindications include known hypersensitivity to theophylline or any excipient listed in the product label.

Relative contraindications and high‑risk situations include severe hepatic impairment, uncontrolled arrhythmias, seizure disorders and significant acute gastric inflammation.

High‑risk groups include elderly patients with reduced clearance and polypharmacy, smokers who have induced clearance, pregnant women assessed for risk versus benefit, and neonates due to immature metabolism.

Practical lifestyle restrictions should be discussed with patients, including limiting caffeine intake because of additive stimulant effects and advising caution with alcohol as it may alter hepatic metabolism.

Driving and operating machinery should be undertaken with caution if dizziness, tremor or palpitations occur while taking theophylline.

• Absolute Contraindication: Known hypersensitivity to theophylline or excipients.
• Relative Contraindications / Precautions: Severe hepatic impairment, uncontrolled arrhythmia, epilepsy, acute gastritis.

Practically, clinicians should follow a short risk assessment flowchart that checks age, liver disease, interacting drugs and smoking status before starting theophylline and plans for intensified monitoring where risk is elevated.

Dosage Guidelines — NHS‑Aligned Regimens, Adjustments And TDM

One of the most common concerns is how dosing is selected and how blood tests are timed.

Typical adult dosing depends on formulation type; immediate‑release schedules need multiple doses per day while prolonged‑release preparations allow once‑ or twice‑daily dosing.

NHS practice emphasises individualised dosing based on weight, age, smoking status and hepatic function.

Traditional therapeutic plasma concentrations are cited as 10–20 μg/mL (10–20 mg/L), with many UK centres aiming for the lower end for chronic therapy and higher targets only in acute situations.

Therapeutic drug monitoring is routine; obtain a steady‑state trough level after about 2–3 days for immediate‑release and 3–7 days for prolonged‑release formulations or sooner after dose changes or interacting drug starts.

Dose adjustments are required for elderly patients, those with liver disease and when interacting inhibitors are commenced.

Smoking induces clearance and often necessitates higher doses, whereas smoking cessation reduces clearance and can precipitate toxicity unless the dose is reduced.

Checklist for TDM timing and interpretation should include baseline liver function, trough sampling at steady state, re‑check after interacting drugs or dose changes, and action thresholds for dose reduction or stopping if levels exceed the therapeutic range or if toxicity appears.

Interactions Overview — Drug–Drug And Food/Drink Interactions

Patients and clinicians alike ask which medicines and foods to avoid with theophylline.

Theophylline is metabolised mainly by CYP1A2 and is susceptible to clinically important interactions.

CYP1A2 inhibitors raise theophylline levels and increase the risk of toxicity; common examples in practice include ciprofloxacin, fluvoxamine and some macrolide antibiotics.

CYP1A2 inducers such as carbamazepine, rifampicin and cigarette smoking lower theophylline levels and may reduce efficacy.

Pharmacodynamic interactions also matter; co‑prescribing some beta‑blockers and antiarrhythmics can increase cardiovascular risk when combined with theophylline.

Caffeine potentiates stimulant adverse effects such as tremor, insomnia and palpitations and should be limited.

Recent MHRA Yellow Card reports often cite macrolide antibiotics and fluoroquinolones as common precipitating causes of theophylline toxicity seen in primary care.

For safe prescribing, include a concise interaction checklist in patient leaflets and use electronic prescribing flags for high‑risk drug combinations.

Cultural Perceptions And Patient Habits In The UK — Patient Forums And Pharmacist Roles

People often want to know what other patients say and how pharmacists support theophylline use.

Online forums in the UK show mixed experiences; many patients see theophylline as an older oral option while some value the convenience of tablets.

Common patient comments include improvement in daily activity for some COPD patients and frustration with systemic side effects and blood tests among others.

Community pharmacists are trusted local medication experts and routinely counsel on interaction risks and TDM logistics.

NHS 111, practice nurses and community pharmacists are commonly first points of contact for initial symptom advice about respiratory medicines.

Electronic prescribing and NHS patient portals such as the NHS App support sharing TDM results and dosing reminders for patients monitored by the service.

• Patients In Scotland, Wales And Northern Ireland: Prescription exemptions can influence adherence compared with England.
• Pharmacist Counselling Checklist: Explain purpose and benefits, dosing schedule, timing of blood tests, interaction risks, lifestyle advice and warning signs of toxicity.

Pharmacists play a central role in ensuring the monitoring plan is communicated and that patients know where and when to have blood tests taken.

Availability And Pricing Patterns — Community Pharmacy And NHS Differences

Many customers ask whether they can buy theophylline directly and how much it costs.

Theophylline formulations are stocked by major pharmacy chains and by NHS hospital and community pharmacies on prescription.

Under NHS arrangements theophylline is typically prescription‑only in England, while Scotland, Wales and Northern Ireland have prescription exemptions that reduce patient out‑of‑pocket costs.

Generics keep the unit drug cost low for commissioners; however, total treatment costs include TDM laboratory fees, clinic time and the potential cost of hospital admissions for toxicity.

Online pharmacies increasingly supply chronic prescriptions via electronic repeat dispensing, but safe supply requires that monitoring plans are documented and followed.

In our online pharmacy, theophylline is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Comparable Medicines And Prescribing Preferences — NHS Alternatives

Patients often ask what alternatives exist to theophylline and why a clinician might choose them.

Primary alternatives in NHS respiratory care are inhaled long‑acting bronchodilators (LABA/LAMA), inhaled corticosteroids and biologic agents for severe eosinophilic asthma.

For systemic oral adjunct options, low‑dose azithromycin is used in selected COPD phenotypes and oral beta‑agonists have limited contemporary use.

Theophylline’s advantages are oral dosing and low generic drug cost; its disadvantages are the narrow therapeutic index, the need for TDM and interaction risks.

Prescribers commonly reserve theophylline when inhaled therapy is inadequate, when adherence to inhalers is poor or when other systemic options are unsuitable.

FAQ — Common NHS Patient Questions With Short Answers

How will I know my dose is safe?

Your clinician will arrange blood tests (therapeutic drug monitoring) after steady state is reached and after dose or medication changes; target troughs usually 10–20 μg/mL but individual targets may vary.

Can I drink coffee or alcohol?

Limit caffeine from tea, coffee and energy drinks because it increases stimulant effects; avoid excess alcohol as it may affect liver metabolism and theophylline levels.

What if I miss a dose?

Take as soon as remembered unless it is near the next scheduled dose; do not double up and seek advice if multiple doses are missed.

Will smoking affect it?

Yes; smoking induces theophylline clearance and may require higher doses, while smoking cessation reduces clearance and usually necessitates dose reduction to avoid toxicity.

Where can I find more information?

Refer to NHS and MHRA guidance and ask your pharmacist for local monitoring arrangements and blood test contacts.

Guidelines For Proper Use — Pharmacist Counselling Style And NHS Patient Support

Pharmacists should open consultations by asking what the patient hopes to get from treatment and whether they have concerns about blood tests or side effects.

Counselling must cover purpose and expected benefits, the dosing schedule (IR vs PR), and the necessity and timing of blood tests.

Provide a clear interaction checklist covering prescription and OTC medicines and common food and drink, especially caffeine.

Advise on lifestyle measures such as limiting caffeine and alcohol and caution around driving if dizziness or palpitations develop.

Highlight warning signs of toxicity including persistent nausea, palpitations, tremor, confusion or seizures and explain when to seek urgent care.

• Pharmacist Counselling Checklist: Purpose, Dosing, TDM Schedule, Interaction Checks, Lifestyle Advice, Warning Signs, Local Phlebotomy Contacts.
• Printable Patient Leaflet Template: Short definitions (therapeutic range, trough level), blood test schedule, emergency contact numbers, Yellow Card reporting link.

Electronic prescribing systems should flag theophylline as a narrow therapeutic index drug to prompt monitoring alerts and support safe repeat dispensing on the NHS.

Delivery Across United Kingdom